Tivic Health Systems (TIVC) said Tuesday it has enrolled a first subject in the optimization study for its patent-pending non-invasive vagus nerve stimulation device.
Conducted by The Feinstein Institute of Bioelectronic Medicine, the study aims to determine the optimal device settings, such as frequency and treatment duration for influencing autonomic nervous system function, the company said, adding that the enrollment is anticipated to be completed by early December.
Shares of Tivic Health Systems were up 1.7% in recent Tuesday trading.
Price: 0.30, Change: +0.01, Percent Change: +1.69
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments